SHU-WEN LINCHUN-JUNG LINJYH-CHIN YANG2021-06-042021-06-04201714656566https://www.scopus.com/inward/record.uri?eid=2-s2.0-85026355707&doi=10.1080%2f14656566.2017.1353079&partnerID=40&md5=2b643235e423c2797250069ee116996fhttps://scholars.lib.ntu.edu.tw/handle/123456789/565064Introduction: Rifamycin SV MMX?, a non-absorbable rifamycin antibiotic formulated using the multi-matrix system, was designed to exhibit its pharmacological action on the distal small intestine and colon. Its clinical efficacy and safety profile in the treatment of traveler’s diarrhea were evaluated in several clinical studies. Areas covered: This review summarizes all available evidence regarding clinical trials of the efficacy and safety profile of rifamycin SV MMX for the treatment of traveler’s diarrhea. Expert opinion: Rifamycin SV MMX demonstrated an excellent pharmacokinetic profile with decreased systemic toxicity similar to rifaximin. In phase II and phase III clinical trials, concerns have been raised regarding the medicine’s efficacy in terms of the time to last unformed stool and cure rate compared to current recommended antibiotics in the treatment of acute diarrhea caused by diarrheagenic Escherichia coli and invasive pathogens. The significance of the increase in MICs after the use of rifamycin SV MMX warrants further examination. ? 2017 Informa UK Limited, trading as Taylor & Francis Group.[SDGs]SDG3alanine aminotransferase; DNA directed RNA polymerase; rifamycin; rifaximin; antiinfective agent; rifamycin; abdominal cramp; abdominal distension; antibiotic therapy; antimicrobial activity; Article; constipation; diarrhea; drug efficacy; drug formulation; drug mechanism; drug metabolism; drug resistance; drug safety; drug structure; Gram negative bacterium; Gram positive bacterium; headache; hearing impairment; human; liver toxicity; minimum inhibitory concentration; Mycobacterium; pharmacodynamics; phase 2 clinical trial (topic); phase 3 clinical trial (topic); pruritus; side effect; traveller diarrhea; treatment indication; xerostomia; clinical trial (topic); diarrhea; microbial sensitivity test; microbiology; travel; treatment outcome; Anti-Bacterial Agents; Clinical Trials as Topic; Diarrhea; Humans; Microbial Sensitivity Tests; Rifamycins; Travel; Treatment Outcomejournal article10.1080/14656566.2017.1353079286973132-s2.0-85026355707